SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-133252
Filing Date
2024-05-07
Accepted
2024-05-07 16:51:10
Documents
15
Period of Report
2024-05-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d810702d8k.htm   iXBRL 8-K 27709
2 EX-99.1 d810702dex991.htm EX-99.1 3971
  Complete submission text file 0001193125-24-133252.txt   192410

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240507.xsd EX-101.SCH 3889
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20240507_def.xml EX-101.DEF 13702
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240507_lab.xml EX-101.LAB 22682
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240507_pre.xml EX-101.PRE 14670
18 EXTRACTED XBRL INSTANCE DOCUMENT d810702d8k_htm.xml XML 5745
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 24922870
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)